A recent study estimating social costs due to work productivity loss, with ribociclib + endocrine therapy among premenopausal women with HR+/HER2- advanced breast cancer, has also been conducted from the Brazilian perspective. This evidence concerns the gene ERBB2 and breast carcinoma.